摘要
目的 评价MVP方案化疗和放疗交替治疗Ⅲ期非小细胞肺癌 (NonSmallCellLungCan cer,NSCLC)的疗效。方法 73例经病理或细胞学证实Ⅲ期NSCLC患者 ,随机分为两组 :39例化疗放疗交替 (化放组 ) ,先用MVP方案化疗一疗程 ,化疗结束后放疗 ,常规分割 ,每日 1次 ,每次 1.9～2 .0Gy,每周 5次。原发灶及淋巴结受累部位 6 0～ 6 5Gy,淋巴引流区 5 0Gy。放疗结束再用MVP方案化疗 5疗程。 34例单纯放疗 (单放组 ) ,放疗方案同化放组。结果 化放组、单放组完全缓解率、部分缓解率分别为 10 .2 % (4/ 39) ,5 6 .4% (2 2 / 39) ;2 .9% (1/ 34) ,5 2 .9% (18/ 34) ,P >0 .0 5。 1、2、3年生存率分别为 94.9% (37/ 39)和 83 .4% (2 8/ 34) ;5 1.2 % (2 0 / 39)和 32 .3 % (11/ 34) ;35 .9% (14/ 39)和 8.8%(3/ 34) ,1、2年生存率差异无统计学意义 (P >0 .0 5 ) ,3年生存率差异有统计学意义 (P <0 .0 5 )。化放组和单放组的白细胞下降 ,放射性食管炎 ,放射性肺炎、肺纤维化 ,差异无显著意义 (P >0 .0 5 )。结论 MVP方案化疗和放疗交替治疗Ⅲ期非小细胞肺癌 ,3年生存率优于单放组 。
Objective To evaluate the curative effect of alternating chemotherapy and radiotherapy for stage Ⅲ non small cell lung cancer (NSCLC).Methods 73 cases of patients stage Ⅲ NSCLC were randomly divided into two groups: 39 patients received MVP chemotherapy (CT) followed by radiotherapy (RT), that is CT-RT group. After one course of chemotherapy, all patients received radiotherapy, 1.9～2.0?Gy every time, five times every week, the total dose of radiation was 60～65?Gy for the primary focus and involving lymph nodes, 50?Gy for lymph drainage area.34 patients received RT alone (RT group).Results The complete remission rate of CT-RT group was 10.2% (4/39), that of RT group was 2.9% (1/34).The partial remission rate of CT-RT group was 56.4% (22/39), that of RT group was 52.9% (18/34).There were no significant difference (P>0.05) between two groups. 1,2,3-year survival rates of CT-RT group and RT group were 94.9%,51.2%,35.9%; 82.4%, 32.3%,8.8%. The difference of 3-years survival rate was significant in statistics (P<0.05). Toxicity in both groups was similar. Conclusions The result shows that alternating chemotherapy with radiotherapy for stage Ⅲ NSCLC is acceptable method and the 3-years survival rate is superior to radiotherapy alone.
出处
《齐齐哈尔医学院学报》
2001年第9期979-980,共2页
Journal of Qiqihar Medical University
关键词
非小细胞肺癌
化疗
放疗
联合治疗
Non small cell lung cancer Chemotherapy radiotherapy Combined treatment
